ST Pharm announced on Thursday that it participated in both TIDES USA 2026 and the world’s largest American Society of Gene & Cell Therapy (ASGCT) 2026 events. These conferences were held simultaneously at the Hynes Convention Center in Boston from May 11 to 14.
TIDES USA is a premier global event that covers research and development (R&D), manufacturing (CMC), and regulatory strategies in the fields of oligonucleotides, peptides, mRNA, and gene editing. It’s recognized as one of the largest industry forums, drawing key companies and decision-makers from the nucleic acid therapeutics sector.
At TIDES USA, ST Pharm demonstrated its contract development and manufacturing organization (CDMO) prowess through presentation sessions for numerous global clients. The company garnered significant attention by sharing its sophisticated development and production strategies. These strategies go beyond mere capacity expansion, aiming to address the burgeoning market for next-generation nucleic acid therapeutics.
During the event, ST Pharm operated a booth to showcase its CDMO capabilities in various nucleic acid therapeutic fields to global clients. The company engaged in a series of business meetings to expand new project acquisitions and strengthen strategic partnerships. These efforts were based on their comprehensive services spanning from preclinical and early clinical stages to commercial production.
Concurrently, ST Pharm sent key personnel to ASGCT 2026. This allowed the company to stay abreast of the latest technological trends in advanced gene and cell therapies, beyond oligonucleotide-based treatments. The team also promoted ST Pharm’s innovative LNP and next-generation nucleic acid therapeutic platform technologies to global pharmaceutical and biotech companies.
A spokesperson for ST Pharm stated that it leveraged all the business capabilities to implement a two-track networking strategy during these concurrent global events, TIDES USA and ASGCT. They added that the goal is to further solidify the strategic collaborations with global clients and accelerate the expansion of the mid- to long-term order pipeline.
ST Pharm, a subsidiary of the Dong-A Socio Group, is a CDMO specializing in active pharmaceutical ingredients (API) and nucleic acid therapeutics. The company is expanding its contract development and manufacturing business, targeting global pharmaceutical and biotech companies. Their focus is on next-generation nucleic acid therapeutics, including oligonucleotides and mRNA.
